Allakos Inc (Allakos) is a clinical-stage biotechnology company that develops antibodies that target immunomodulatory receptors present on immune effector cells. The company investigates the therapeutic areas of eosinophilic gastrointestinal diseases, chronic inflammatory diseases with continuing gastrointestinal symptoms along with an increase in the count of mast cells in the body. Its product offerings include AK002, an antibody that targets Siglec-8, an inhibitory receptor for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic and mastocytosis. The company is discovering AK007 to treat immuno-oncology disease. It partners with universities ad pharmaceutical companies. Allakos is headquartered in Redwood City, California, the US.
Headquarters
United States of America
Address
825 Industrial Road, Suite 500, San Carlos, California, 94070
Website
www.allakos.com
Telephone
1 650 5975002
No of Employees
131
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALLK (NASD)
EPS
XYZ
Net Income (2022)
XYZ
42%
(2022 vs 2021)
Market Cap*
$93.2M
* As of and is in US$
Allakos Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| AK002: |
| Allergic, Inflammatory and Proliferative Diseases |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In November, the company announced its plans to raise up to US$250 million in public offering of common stock. |
| 2022 | Others | In May, the company announced the filing for offering of up to US$250 million shares of common stock. |
| 2021 | Others | In November, the company initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial of subcutaneous (SC) lirentelimab in adult patients with moderate-to-severe atopic dermatitis. |
Competitor Comparison
| Key Parameters | Allakos Inc | F. Hoffmann-La Roche Ltd | Pfizer Inc | AbbVie Inc | Sanofi |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | France |
| City | San Carlos | Basel | New York | North Chicago | Paris |
| State/Province | California | - | New York | Illinois | Ile-de-France |
| No. of Employees | 131 | 103,605 | 88,000 | 50,000 | 87,994 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Daniel Janney | Chairman | Executive Board | 2017 | 57 |
| Robert Alexander | Chief Executive Officer; Director | Executive Board | 2017 | 53 |
| Baird Radford | Chief Financial Officer | Senior Management | 2021 | 53 |
| Craig Paterson | Chief Medical Officer | Senior Management | 2021 | 58 |
| Adam Tomasi | President | Senior Management | 2019 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward